EXTON, Pa., Sept. 26, 2018 (GLOBE NEWSWIRE) — Fibrocell Science, Inc., (NASDAQ: FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, today announced that John Maslowski, President and Chief Executive Officer, will present at these industry and investor conferences in October 2018:
- Cell & Gene Meeting on the Mesa on Wednesday, October 3rd at 3:00 p.m. PDT in La Jolla, CA
- Chardan 2nd Annual Genetic Medicines Conference on Tuesday, October 9th at 7:30 a.m. EDT in New York City
A live webcast of each Fibrocell presentation will be available under the investor relations section of the Company’s website at www.fibrocell.com/investors/events, and will be archived for 30 days following each event.
Fibrocell is an autologous cell and gene therapy company translating personalized biologics into medical breakthroughs for diseases affecting the skin and connective tissue. Fibrocell’s most advanced product candidate, FCX-007, is the subject of a Phase 1/2 clinical trial for the treatment of recessive dystrophic epidermolysis bullosa (RDEB). Fibrocell is also developing FCX-013, the Company’s clinical stage candidate for the treatment of moderate to severe localized scleroderma. Fibrocell’s gene therapy portfolio is being developed in collaboration with Precigen, Inc., a wholly owned subsidiary of Intrexon Corporation (NASDAQ: XON), a leader in synthetic biology. For more information, visit www.fibrocell.com or follow Fibrocell on Twitter at @Fibrocell.
Fibrocell®, the Fibrocell logo, and Fibrocell Science® are trademarks of Fibrocell Science, Inc. and/or its affiliates. All other names may be trademarks of their respective owners.
Investor Relations Contact: